Home / Transcripts / Research Solutions, Inc. (RSSS) · May 14, 2026

Research Solutions, Inc. (RSSS) Earnings Call Transcript & Summary

May 14, 2026

NASDAQ US Information Technology IT Services earnings 32 min

What were the key takeaways from Research Solutions, Inc.'s May 14, 2026 earnings call?

In the third quarter of fiscal 2026, Research Solutions, Inc. reported total revenue of $12.1 million, a decline from $12.7 million in the same quarter last year. Despite this, the company achieved a significant increase in net income to $860,000, or $0.03 per diluted share, compared to $216,000, or $0.01 per diluted share, in the prior year, marking a 297% increase. Management highlighted strong new bookings, with 61 new or upsell logos generating $961,000 in annual recurring revenue (ARR), although this was offset by a churn of 46 logos representing $398,000 in ARR. The company maintained its focus on improving churn and expects to exit fiscal 2026 with stronger earnings power and cash generation.

What topics did Research Solutions, Inc. cover?

What were Research Solutions, Inc.'s May 14, 2026 results?

Research Solutions demonstrated resilience in profitability despite revenue challenges, with a clear focus on improving customer engagement and leveraging AI for future growth. The company’s ability to manage costs effectively and enhance its product offerings positions it well for potential recovery in the upcoming quarters. Investors should monitor churn metrics and the success of new product integrations as key indicators of future performance.

Earnings Call Speaker Segments

John Beisler executive
#1

Thanks, operator. Good afternoon, everybody. We appreciate you being with us today for the earnings call covering Research Solutions' third quarter of fiscal year 2026. Joining us are Roy W. Olivier, who serves as President, Chairman, and Chief Executive Officer, along with Dave Kutil, our Chief Financial Officer. The company put out a press release after the market shut this afternoon announcing results for the third quarter of fiscal 2026. You can find that release on the company's website, researchsolutions.com. Before Roy and Dave deliver their prepared comments, I want to note that certain statements today will be forward-looking and are being made under the Private Securities Litigation Reform Act of 1995. Because of a range of factors, actual results could differ materially from what is expressed or implied; for a more detailed discussion of the risks and uncertainties that might affect the company's future operating results and financial conditions, we point you to Research Solutions' recent filings with the SEC; in addition, on today's call, management will reference certain non-GAAP financial measures, which we believe provide useful information for investors. Today's earnings press release also includes a reconciliation of those measures to GAAP measures. Lastly, I want to remind everyone once more that this call is being recorded and made available for replay through a link on the company's website. I'll now hand the call over to Roy W. Olivier. Roy?

Roy Olivier executive
#2

Thanks, John. During Q3, we saw EBITDA and net income get better, though the top line growth was definitely below what we had hoped for. Churn remains something we need to address, and I'll get into that more later on this call. On the positive side, new bookings came in at 61 new or upsell logos, which works out to $961,000 in ARR. Sadly, we lost 46 logos to churn, amounting to $398,000 in ARR. The majority of those were smaller accounts. That said, 1 large account within that group accounted for roughly $130,000. Just to remind everyone, roughly 1/3 of churn can't be controlled; that portion mostly happens when one of our customers gets acquired, shuts down, or goes through a reorg that involves cutting the research function. The other 2/3 is controllable, and that's where we're putting our attention, and none of it has anything to do with "AI usage". There was plenty of positive news this quarter. Both academic and corporate sales performed well. We closed significant academic agreements in Johannesburg, Singapore, and a number with leading U.S. universities, among them my alma mater, Texas A&M. These are mostly Scite deals. We also closed a number of large corporate deals at prices either well above or right at historic average sales price, or ASP. That's a healthy blend of Scite and Article Galaxy deals. Roughly 70% of those are AG deals. What matters is that new bookings are performing well, and I'm optimistic about our new bookings growth. We've been applying AI internally across practically every part of the business. As a result, the product teams have enjoyed a solid gain in productivity. Because of this, we're now able to hand software development issues off to AI and then have a developer verify that work; this has sped up how many new items go into each release; on top of that, we launched 2 new AI-based products during the quarter; they're known as MCPs, which stands for Model Context Protocol. Think of an MCP as being like a software API, except it's a connector for plugging an AI-based LLM such as ChatGPT or Claude, or an LLM built in-house, into Article Galaxy or Scite. This fits within our headless strategy, meaning we want to be present wherever our customers are doing their work. I'll cover that in more depth later in the call as well. I'll go through all of this with you in somewhat greater detail shortly, but right now, I'll let Dave take you through the results more thoroughly. Dave?

Dave Kutil executive
#3

Thanks, Roy, and good afternoon to all of you. For the third quarter of fiscal 2026, total revenue came in at $12.1 million, versus $12.7 million during the same quarter in fiscal 2025. Gains in platform subscription revenue were more than canceled out by a downturn in our lower-margin transactions business. Platform subscription revenue rose roughly 7%, reaching $5.2 million. That increase came mainly from a net addition of 15 platform deployments relative to the prior year, plus expansion among customers we already had through upsells and cross-sells. Roughly 43% of total revenue this quarter came from the platform side, up from about 38% a year earlier, as the mix keeps tilting toward the higher-margin platform business. We closed the quarter with annual recurring revenue, or ARR, of $22.1 million, an 8.5% increase year-over-year, made up of about $15.7 million in B2B ARR and about $6.4 million in normalized ARR tied to Scite's B2C subscribers. Even though B2C ARR fell 7.5% year-over-year, recent months have brought signs of improvement, since the MCP launch Roy referenced earlier has lifted both conversion and retention. Net incremental platform ARR during the quarter was roughly $317,000. Definitions and usage for annual recurring revenue and other non-GAAP items can be found in today's press release. Transaction revenue for the third quarter totaled $7.0 million, compared with $7.8 million a year earlier. The weakness stemmed from an account churn we discussed previously along with volume declines at a handful of larger customers; worth noting is that the monthly trend within the quarter demonstrated meaningful directional improvement, and though it does not amount to a full recovery, it represents an early sign of stabilization. Our total active transaction customer count for the quarter was 1,346, versus 1,380 during the same period last year. Third quarter gross profit was $6.3 million, essentially flat in dollar terms against the prior year quarter despite lower revenue. Gross margin reached 51.7%, an improvement of 220 basis points over the third quarter of fiscal 2025. That gain came primarily from the continuing shift in revenue mix toward our higher-margin platforms business; measured on a trailing 12-month basis, the company's blended gross margin now sits at 51.4%. The platform business posted a gross margin of 86.4%, down from 87.4% a year earlier, which reflects modest hosting and infrastructure investments supporting our AI and integration road map, and remains comfortably within our high-to-mid 80% target range. Gross margin in our transaction business was 26%, essentially unchanged from the third quarter of fiscal 2025. Total operating expenses for the quarter were $5.2 million, compared with $5.7 million in the prior year quarter. That improvement came mainly from lower general and administrative expenses and reduced stock-based compensation, partly offset by continued investment in sales, marketing, and product. This offers further proof that the company's profitability gains are not merely emanating from margin mix. They also reflect our operating discipline. When it comes to G&A spending, we're taking a careful approach—holding it in check while directing resources toward growth efforts. That discipline should show up as ongoing operating leverage. For the quarter, net income came in at $860,000, which works out to $0.03 per diluted share. In the same quarter a year earlier, net income was $216,000, or $0.01 per diluted share—a rise of roughly 297%. Adjusted EBITDA for the quarter reached $1.6 million, up 14% from $1.4 million in the year-ago quarter. Measured on a trailing 12-month basis, our adjusted EBITDA margin was 12.3%, which is 220 basis points higher than in the prior year quarter. Trailing 12-month adjusted EBITDA is now $6 million. Let's move to the balance sheet. At quarter end, cash and cash equivalents totaled $12.1 million, basically flat versus our 2025 fiscal year-end, and that's after we funded the Scite earnout payments during the first 9 months of fiscal 2026. Those payments comprised about $3.7 million in cash plus the issuance of roughly 739,000 shares of stock. We closed the quarter with nothing drawn on our revolving line of credit, which gives us added flexibility on the balance sheet. Cash flow from operations for the quarter was $1.0 million, versus $2.9 million in the prior year quarter. That decrease stems from the timing of customer billings and strategic prepays, not from any shift in underlying earnings power or in how collectible our receivables are. Trailing 12 months cash flow from operations was $5.7 million. As we head into the last quarter of fiscal 2026, our goal is to deliver adjusted EBITDA growth over the prior year, fueled by continued platform subscription growth, better retention, increasing stabilization in transactions, and disciplined expense management. We anticipate exiting fiscal 2026 with greater earning power and cash generation, which underscores how durable our Software-as-a-Service platform model is and our capacity to invest behind the next phase of growth. I'll now hand the call back to Roy. Roy?

Roy Olivier executive
#4

Appreciate that, Dave. One note before I go on — Josh, who's usually on these calls, isn't with us today. His wife gave birth last week, so he's at home looking after the newborn. Now, back to B2B bookings. Things are going well for both the academic and corporate teams. Just to remind everyone, the academic focus team was built out in 2025, or fiscal year '25. The corporate team has existed for a great many years. During the quarter, the corporate team performed well, booking roughly $400,000. The academic team brought in approximately $265,000, despite this being a seasonally slow period for them. The rest, or the balance, of the new bookings came from the CSM upsell-renewal team. Many salespeople on those teams are recent hires or have less than a year of tenure, but results are still where they should be and are improving. B2B churn, as I mentioned before, is the primary factor limiting top line growth. To address it, we're doing a number of things: reorganizing the team, directing more resources toward it, bringing in new technology that lets us move from reacting to problems to getting ahead of them, and identifying users with low usage so we can start workflows aimed at drawing them back in. Finally, we're improving onboarding and training to boost customer adoption. This won't be resolved within a single quarter, but I have strong confidence in our approach to restoring it to levels we've seen historically. There's more we can get into on that topic when we talk again next quarter. Turning now to B2C, conditions have started looking better than what we saw in earlier periods. The improvements we made to the product, along with those new AI-driven offerings I brought up earlier, played a role in turning around what had been a consistent downward trend for that part of the business. Even though we brought in fewer new trials while spending much less on digital, our MRR has stayed roughly level compared with the previous quarter. We've cut CAC by roughly 24%, while LTV has risen. The early part of Q4 looks promising, though you should remember that the slow period is coming as schools break for the summer months. Even so, we've got several promising fresh iterations of the B2C offering, and those are expanding at a solid pace. For us, everything stems from product strategy and innovation. We've kept making both Scite and AG better. As a reminder, there are three ways we deliver value from Scite and AG. The first is to customers who directly license the software and use it every day. The second is that we offer that same functionality and value through software APIs, for customers who've built their own solutions in-house but need our unique capability at certain points in that workflow. As we've said before, the third option is the new 2 AI-based products that link AI LLMs to the product; again, these are called MCPs, and they're 1-click connectors that let the value of Scite and AG operate inside an LLM. They're using ChatGPT and Claude at the moment. At present, this is live for every B2C user along with a portion of our B2B users. If I circle back to the headless strategy we talked about during previous quarters — being present wherever customers happen to be — many of our users are starting to work within an LLM. They can ask that LLM a question and then interact with Scite content in a way that keeps copyright respected. Once they get an answer that includes complete citations, they're able to ask the LLM for the articles, and it will connect with Article Galaxy to pull that content for the user, all while maintaining copyright compliance. Essentially, this enables an LLM to collaborate with Article Galaxy and/or Scite, once again, in a way that complies with copyright. This is going to be a significant driver of our growth going forward. Roughly 2 months have passed since the Scite MCP launched, and the AG MCP came out a month ago. Already, we have a sales pipeline exceeding $1 million in opportunities tied to these new products. These MCPs are designed to serve academic as well as corporate customers. On top of that, we've brought the Resolute databases into these MCPs. As a reminder, we acquired Resolute roughly 2 years back, and 1 of the assets from that deal was access to more than a dozen curated databases tied to research. We've now incorporated those into our MCP. So when someone poses a question within the AI tool, the response the tool gives today will incorporate patents, clinical trial, and major grant data. What this means is that users can — no, sorry, that's the wrong page — can begin and finish their research journey inside whichever AI LLM they prefer. There is an enormous amount of enthusiasm both internally and among our customer base regarding these databases being brought in. We'll share news of further data sets as we bring them on. Making the unique value we offer available wherever our customers conduct research will stay at the heart of our strategy. Put simply, AI won't do away with research, but it will alter the way it's accessed. Turning to document delivery, or DocDel, we anticipate seeing betterment in Q4 when it comes to FY — apologies, when it comes to year-over-year performance. As mentioned during prior earnings calls, a small number of customers were responsible for the bulk of this decline. We had a large customer churn that's driving the year-over-year drop, and a few other customers are conducting less research than they were a year ago. Beyond that group of clients, DocDel is expanding—particularly the OA and other no-cost DocDel offerings—although the paid version has softened a bit. When it comes to M&A, we continue to hunt for attractive targets and are gaining traction on several. That said, our current TTM enterprise value to revenue multiple sits between 2.7x and 3.4x, with the exact figure hinging on the value assigned to the DocDels. As a result, matching the multiples that sellers want is difficult, since those expectations stay tied to pre-SaaS software valuations, which are eroding amid AI-related concerns. In closing, Q3 brought cash flow, net income, EBITDA, sales execution, and product progress that leave me encouraged. I don't believe our numbers capture the excellent work we're delivering in those areas. My belief is that you'll see that improvement emerge during upcoming quarters, as well as in FY '27. At this point, I'll hand things to the operator so we can take questions. Operator?

Jacob Stephan analyst
#5

Roy, I suppose I'll start by asking about B2B churn for a moment. Clearly, this sounds like a strong quarter for new logos, though it was held back by some of that churn. That said, what exactly are the pain points for customers? What reasons are you hearing from them behind the churn?

Roy Olivier executive
#6

Fundamentally, it boils down to customers whose engagement is limited; put differently, we aren't seeing much platform usage, or, in Article Galaxy's situation, they aren't buying sufficient articles for the ROI to justify the platform. In some instances within this economy, customers are just seeking ways to reduce spending. They might not be a large research organization, yet they still want to trim the costs tied to conducting that work. As for us, the priorities going forward involve strengthening onboarding and training so that by the close of a 90-day window, most researchers have logged in, used the product, and received training on it. Second, we aim to track product usage, so that whenever we identify a cohort of customers who aren't using the product, we can automatically launch a 3- or 4-point communication to that customer through in-product messaging and email in order to reengage them and get them using the product. Third, we recognize that particular features within our product are very strong renewal features. In other words, those who use specific features in the product rely on them heavily and almost never churn out; therefore, much like with usage, we'll track cohorts of customers who aren't using those features and launch workflows to help them understand those features exist, and to help them understand how to use those features. As for us, most of that churn ties either to an absence of ROI, which can stem from insufficient usage, or can stem from fewer DocDel purchases, along with a lack of engagement on user parts; put differently, they aren't using the product to the extent they had hoped.

Jacob Stephan analyst
#7

Perhaps we could shift to the B2C side for a moment. I realize a seasonal dip is coming now that students are finishing up classes and all that. Could you help me reason through how CAC metrics are getting better? Is it that you're putting less money into marketing while getting stronger conversion? I suppose this is a question of numerator against denominator.

Roy Olivier executive
#8

That's right — our digital ad spending has dropped considerably, and yet we're still watching our conversion rate come out of the funnel. Put differently, that's what generates a trial user. Conversion rates did get better, and that gives us roughly flat MRR while digital spend is far lower. Beyond that, certain releases such as the MCPs we've discussed have made a substantial difference for retention; as a result, those customers remain with us longer, which is why lifetime value has improved. So my view is that if we keep executing on that front, we might get that metric expanding once more.

Jacob Stephan analyst
#9

And perhaps only one — please continue.

Dave Kutil executive
#10

I was about to mention that regarding what we put toward advertising, we have the ability to — I believe I brought this up during the prior call too — we truly can handle that from one week to the next. So we're able to switch it on once we move into the autumn period, when the student group comes back; and afterward, when we get close to summertime, we can be far more intentional about those ad dollars; so that's something we'll keep doing. And genuinely having insight into that and the way it's converting has allowed us to control expenses and also stretch that line while we continue to keep the MRR expanding.

Jacob Stephan analyst
#11

Perhaps this will be my final inquiry. I'm aware that you're pursuing innovation in artificial intelligence, connecting Scite and Article Galaxy via MCPs, plus bringing Resolute into the mix. If you were to project 12 to 18 months ahead, what would your AI road map for launching new products resemble? In which areas do you foresee potential openings for developing new products?

Roy Olivier executive
#12

Correct. Naturally, Scite was built from the ground up as a fully AI-driven platform. In my view, there's room inside the Article Galaxy platform to bring AI in while respecting copyright, accomplishing multiple objectives that reduce friction during research. For clients who rely on AG every day, they could obtain summaries of items stored in a folder, provided they hold the necessary rights; they could obtain a summary of a single article, provided they hold the necessary rights; they could pull out tables and additional details, once again provided they hold the necessary rights. So we'll keep building on that. In my view, there are multiple places within Article Galaxy where we can keep improving by adding AI on top of that workflow. The two MCPs are entirely AI. And I believe the genuine additional benefit there is that we possess approximately 9 or 10 more curated databases from Resolute that we can begin by connecting with those MCPs. Consequently, someone using an MCP will see patent results responding to their query, clinical trial results responding to their query, and eventually we'll bring in those remaining databases, among them drug databases and other databases tied to research that will prove useful for those researchers, who can include them, switch them on, switch them off; these also represent revenue possibilities for us. After that, once they reside within the MCP, which will occur quite rapidly in fact, we'll then return to integrating them into Scite, AG, or both, so that you can access them as part of your search results within Scite or within AG. So it's about continuously incorporating curated, distinctive data into the responses to the questions you pose, should you wish for that inclusion, and providing a wider perspective on everything connected to your inquiry rather than solely scientific research.

Derek Greenberg analyst
#13

First off, I want to ask about the Scite B2C2B pipeline. In prior quarters, you all brought that up. I'm curious whether anything has moved forward there — specifically, what are you observing when it comes to how that pipeline is building out from those opportunities?

Roy Olivier executive
#14

That particular portion of our pipeline wasn't something I looked at. What I reviewed was the MCP piece I referenced during the call. Even so, it remains something that fuels a great deal of our B2B sales, though right now I'm unable to say whether, over the quarter, it rose, fell, or stayed level.

Dave Kutil executive
#15

Sure, I can add a bit more detail there. It ticked up somewhat. We'd been discussing a figure around $100,000, and it rose by roughly 50%. As Roy mentioned, we're beginning to explore some of the newer offerings on the B2C side that will provide users with a bit more MCP usage beyond the basic plan. So we believe that certain power users, and eventually teams with 2 to 50 seats, can be captured within the B2C platform, allowing them to recognize the value of MCP and other features there, and then converting them into B2B as well. So there's a much broader road map on the B2C side. And as I noted in my remarks, retention and engagement improve significantly once we launch MCP. That's another pathway from B2C to B2B.

Derek Greenberg analyst
#16

My next question, then, is how should we think about usage at present regarding the headless strategy? For instance, what are you observing when it comes to the percentage of pulls and usage originating outside your core platforms — within customers' own workflows rather than on the platform? And as these new technologies get adopted more, what do you anticipate that mix will look like over time?

Roy Olivier executive
#17

Yes. With the MCP products, the usage we observe is a multiple higher than what our own products see. After integration, they're plugged into every user who's hammering away at an LLM — be it Claude or ChatGPT — all day long, daily; so in certain cases we're absolutely seeing usage that is literally a fairly large multiple above what a typical enterprise customer of equivalent size, or with the same count of user seats, would show us. One thing I'd add — a side effect or something tied to what Dave brought up — is that we're setting the product up with usage-based pricing. So MCPs from us aren't essentially unlimited. A cap exists; once you reach that cap, you must shift to a larger cap in pricing terms, since we genuinely believe that as we move through this transition away from our historic SaaS software and API business toward increasingly MCP-associated revenue, that revenue will be generated according to usage, which, as I said, is a multiple of the SaaS software platform. And we want to ensure we aren't attempting to sell a seat product into a setting with 10x the usage while failing to capture, in revenue to us, the value of that usage, if that's helpful.

Derek Greenberg analyst
#18

Then here's the final thing I wanted to ask. Earlier, you mentioned that you were looking at the possibility of making sales into segments that are new for you, things like financial institutions, hedge funds, and investment banks, for their research needs. Have you noticed any traction in those areas, or in any other new areas, and do you have anything to say about that?

Roy Olivier executive
#19

In those segments, we have a few cats and dogs. At this moment, though, our new sales groups are heavily concentrated on corporate and academic, and I'm reluctant to take people away from what looks like a fairly strong pipeline and a fairly strong TAM in order to chase these other verticals, except when we're responding to inbounds coming from those other verticals. So should we spot one that we genuinely believe will produce results, we might bring on more salespeople dedicated solely to those markets, but as of now that step hasn't been taken.

Roy Olivier executive
#20

Okay, thank you all for being here. Just a note that on June 10, we’ll be at the Three Part Advisors IDEAS Conference in New York. If you’re a qualified investor who wants to attend, please contact Three Part Advisors so we can get you scheduled. We’re looking forward to talking with you in September and going over the fourth quarter and full fiscal year results. Have a great day.

Operator operator
#21

Thanks. That wraps up the session for today. We’re grateful for the time you’ve given and for joining in. You’re welcome to hang up now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Research Solutions, Inc. transcript - plus 131,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Research Solutions, Inc. earnings transcripts and 131,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.